Medicines Australia firmly oppose US tariffs on pharmaceuticals

Medicines Australia firmly oppose US tariffs on pharmaceuticals

3 April 2026: Medicines Australia and our members support free, fair, and open trade and firmly oppose the proposed introduction of 100% tariffs on Australian branded and patented medicines exported to the US.

“Decades of decline in local manufacturing means the companies Medicines Australia represents do not significantly export to the US. Our understanding also is that CSL will be exempt for 2026. So proposed Tariffs are more likely to impact a relatively small number of Australian companies seeking opportunity in the US market,” states Liz de Somer, CEO.

According to Australian Government data, Australia has a pharmaceutical trade deficit with the US. In 2025, Australia exported around A$1.91 billion in pharmaceutical products to the United States (US) but imported A$3.34 billion.

“As an industry, we are more concerned with President Trump’s Most Favoured Nation reference pricing benchmark proposal as Australia currently has some of the lowest pharmaceutical prices, compared to other OECD countries,” adds Ms de Somer.

“This is already impacting Australian patients’ access to new innovative treatments, with companies introducing revised global policies which are slowing down new innovative products launching in Australia and exacerbating further delays to listings on the PBS.

“Some countries like the UK, EU and Japan have now undertaken negotiations with the US Administration to address both tariffs and US reference pricing policies. We must now consider the consequences of not addressing these global developments.”

As stated by the Hon Minister Butler this week, the Productivity Commission confirms the 3 per cent a year increase in health productivity is due to improvements in treatment quality — particularly the growing impact of modern medicines that help people recover faster, avoid complications, and stay well for longer.

“This confirms the need to invest in innovative medicines for Australian patients and their families. It has been 30 years since the PBS has been reviewed and updated. We urgently need to move forward with proposed reform recommendations to our Health Technology Assessment (HTA) which includes the PBS,” adds Ms de Somer.

“There is no time to wait. We started this process several years ago and need to work together now to ensure the PBS is faster, fairer and fitter for our future,” she adds.


Media enquiries:
Anne-Marie Sparrow, Medicines Australia /Cube – media@medicinesaustralia.com.au  or 0417 421 560.

About Medicines Australia:
Medicines Australia leads the research-based pharmaceutical industry of Australia. Our members discover, develop and manufacture the medicines that are the foundation of a healthy and prosperous society, including prescription pharmaceutical products, biotherapeutic products and vaccines. Our members invest in Australian medical research and take local discoveries and developments to the world.

Medicines Australia appoints senior media advisor

Medicines Australia appoints senior media advisor

02 April 2026: Medicines Australia is pleased to announce the appointment of Jonathan Hawkes as its new Senior Media Advisor, strengthening the organisation’s media and communications capacities.

Jonathan brings strong media and public affairs expertise from roles including Senior Media Advisor for Senator The Hon Bridget McKenzie, Director of Public Affairs and Campaign Manager for the Minerals Council of Australia and as Federal Director of The Nationals. He has managed many high-profile campaigns and communications projects and is pleased to join Medicines Australia.

“We are delighted to welcome Jonathan to Medicines Australia. Jonathan’s appointment will help further build the capacity of Medicines Australia to advocate for a stronger health system, providing more Australians with access to new, innovative medicines,” said Medicines Australia CEO, Liz de Somer.

Jonathan took on the role on 23rd March 2026.


Media enquiries:
Anne-Marie Sparrow, Medicines Australia /Cube – media@medicinesaustralia.com.au or 0417 421 560.

Jonathan Hawkes, Senior Media Advisor, Medicines Australia – 0434 660 801 or Jonathan.hawkes@medicinesaustralia.com.au

About Medicines Australia:
Medicines Australia leads the research-based pharmaceutical industry of Australia. Our members discover, develop and manufacture the medicines that are the foundation of a healthy and prosperous society, including prescription pharmaceutical products, biotherapeutic products and vaccines. Our members invest in Australian medical research and take local discoveries and developments to the world.

Joint Industry Statement: Australia–EU Agreements Deliver Opportunity Across the Economy

Joint Industry Statement: Australia–EU Agreements Deliver Opportunity Across the Economy

Sydney – 24 March 2026 – leading Australian business, industry, investment and peak body organisations welcome the conclusion of the Australia–European Union Free Trade Agreement, the establishment of the Australia–EU Security and Defence Partnership, and the decision to fast-track negotiations for Australia’s association with Horizon Europe.

These outcomes provide much-needed clarity and confidence at a time when businesses, investors, and researchers are navigating increased global uncertainty, disrupted supply chains and rapid technological change. Together, they strengthen Australia’s links with one of its most important economic partners and expand opportunities for Australian firms across a wide range of sectors.

The EU-Australia Free Trade Agreement will improve access to the world’s largest single market and removes long-standing barriers that have constrained trade and investment. Australian exporters, service providers and investors will benefit from greater certainty, more efficient regulatory settings and improved conditions to operate, compete and scale in Europe.

The benefits extend across the economy. Industries spanning resources and critical minerals, clean energy, advanced manufacturing, agribusiness and food, financial and professional services, digital and technology services, healthcare and life sciences, education, transport and tourism are all well positioned to take advantage of improved market access, deeper commercial partnerships and stronger value-chain connections.

The EU-Australia Security and Defence Partnership reflects the growing intersection between economic activity and national resilience. It supports closer collaboration in areas such as defence industry capability, advanced manufacturing, emerging technologies, cyber and supply-chain resilience – creating new opportunities for Australian businesses to partner with European counterparts in high-value strategic sectors.

Fast-tracking negotiations for participation in Horizon Europe further strengthens this partnership by linking Australian industry, researchers and innovators into one of the world’s most significant research and innovation ecosystems. This collaboration will help drive new ideas from research through to commercial application and support the development of globally competitive industries.

Together, these agreements support investment, innovation and job creation across Australia, including in regional communities where many opportunities in these critical sectors are based.

Business and industry, institutional investors, universities and the research community urge the EU and Australia to swiftly ratify these agreements and expedite their implementation. Peak bodies will work with governments and partners on both sides to ensure these agreements translate into practical outcomes for businesses, workers and communities.

Quotes attributable to peak groups in support of the statement include:

Australian Banking Association, CEO Simon Birmingham:
“Australian banks welcome the conclusion of this landmark free trade deal with one of our most significant economic partners.

Expanding our trading ties with the EU will open new doors for Australian businesses, create stronger links between our financial systems and help boost two-way investment flows.

Importantly, it will also unlock more opportunities and deliver longstanding benefits for Australia’s financial services sector in one of the world’s largest economies.”

Australian Chamber of Commerce and Industry (ACCI), CEO, Andrew McKellar:
“Today’s announcements mark a step forward in Australia’s deep and comprehensive relationship with Europe across trade, investment and innovation.

At a time when partnerships are so crucial, this provides even more options for Australian businesses to grow, expand and capitalise on the opportunities that Europe presents.

Australia’s relationship with Europe is deep and comprehensive. We look forward to studying the details of these agreements more closely.”

Australian Industry Group (Ai Group), CEO, Innes Willox:
“This is the final piece in linking all our major trading partners. It will deliver a multi-billion dollar boost to our economy and will be felt by all sectors – health care, defence, tourism, finance, our innovators and our rich resources and critical minerals.

This is a deal that has taken time to get right and it will deliver long term benefits to all Australians.”

Australian Institute of Company Directors, Managing Director and CEO, Mark Rigotti:
“According to our Director Sentiment Index, around 90 per cent of directors judge that escalating global trade tensions between major economies are likely to threaten both the Australian and global economic outlooks. The AICD supports initiatives such as the FTA and collaboration through Horizon Europe, which deepen Australia’s engagement with Europe and help foster a stable, innovation-led business environment, providing greater certainty for directors navigating an increasingly complex global landscape.”

Australian Retail Council (ARC), CEO, Chris Rodwell:
“The confirmation of the Australia–EU Free Trade Agreement is a win for Australian retailers and consumers. It gives retailers more choice and flexibility in sourcing and new opportunities to expand Australian brands into a market of more than 400 million consumers, while potentially helping ease cost pressures across the supply chain.”

Australian Services Roundtable, President, Holly Dorber:
“Services business dominates this bilateral trade and investment relationship, making the EU market vitally important to Australia’s services export interests.

ASR has consistently championed these negotiations as fundamental to Australia’s economic prosperity in a digital economy.

Digitally-enabled services trade is the crucial generator of future growth, employment and productivity. This long-awaited deal is an undeniable win-win for the two parties.”

Business Council of Australia, Chief Executive, Bran Black:
“This is a major step forward for Australia, strengthening ties with one of our most important economic partners and supporting jobs, growth and higher living standards.”

Together, these agreements will unlock new opportunities across key sectors including clean energy, critical minerals, advanced manufacturing and services – making it easier for Australian businesses of all sizes to grow, partner and compete in one of the world’s largest markets.

This is about positioning Australia for the future. By strengthening our links with Europe on trade, investment and innovation, these agreements will attract investment, create jobs and keep our economy competitive.”

European Australian Business Council (EABC), CEO, Jason Collins:
“Together, the FTA, the Security and Defence Partnership and Horizon Europe represent a step-change in the Australia–EU relationship, aligning economic policy, industrial capability and research excellence into a future-focussed strategic partnership.

These agreements go to the heart of Australia’s long-term prosperity – how we trade, how we innovate, how we build capability, and how we remain globally competitive in a far more contested world.”

Export Council of Australia (ECA), Chair, Dianne Tipping:
“An Australia–EU FTA is a strategic win: it strengthens supply chains, boosts investment, and opens real commercial doors for green tech, construction, engineering, and Indigenous enterprises.

This agreement gives Australian exporters and Investors what they need most – certainty, scale and a clear pathway into one of the world’s largest markets.”

The Group of Eight, Chief Executive & Director, Vicki Thomson
“Association with Horizon Europe would give Australian researchers and industry a front row seat to the world’s most ambitious collaborative research projects.

It would strengthen pathways from discovery to commercialisation, connect Australian innovation directly into European industrial ecosystems, and has the potential to significantly enhance Australia’s global competitiveness.

Horizon Europe is not just a research programme. It is an engine of competitiveness and a bridge between knowledge and industry. Australia’s participation will strengthen both sides.”

International Chamber of Commerce Australia (ICC Australia), Chair, Hon Mark Birrell AM:
“The Australian national committee of the International Chamber of Commerce welcomes the conclusion of negotiations for a free trade agreement between Australia and the European Union. ICC Australia Chair, the Hon Mark Birrell AM, welcomes today’s announcement as a ‘game changer’ in our trade and investment relationship.

At a time of geopolitical uncertainty, it is absolutely vital that we lean in on proven partnerships that have served us well and can underpin mutual prosperity for decades ahead.

Today’s comprehensive announcement attests to the depth of our relationship with the EU and the great scope we have to seize yet more opportunities. On behalf of ICC Australia, I extend congratulations to the Albanese Government and our negotiators on this achievement.”


Medicines Australia (MA), CEO, Liz de Somer:
“Medicines Australia welcomes the conclusion of the Australia – EU agreements, in particular to fast-track negotiations for Horizon Europe.

Horizon Europe offers a myriad of opportunities to work with the EU to unlock substantial new funding opportunities for collaborative research and development, particularly benefiting Australian researchers and businesses.

With international supply chains under real pressure, we must continue to look for new opportunities that will help create jobs, attract investment and improve health outcomes.”

Minerals Council of Australia (MCA), CEO, Tania Constable:
“This is a major boost for Australia’s minerals sector. Removing all tariffs and barriers to trade on resources and critical minerals strengthens Australia’s competitiveness and supports predictable, open trade and investment with a key strategic partner.

This FTA and the existing Australia-EU Strategic Partnership on Critical Minerals position Australia as a reliable, long-term supplier of the minerals essential to energy systems, defence technologies, advanced manufacturing. Australia and the EU are trusted partners in delivering the secure supply chains and industrial resilience for both economies.

The agreement improves market access for Australian miners, enhances investment certainty and provides a strong platform for increased investment into mining projects, downstream processing and critical minerals supply chains in both Australia and the EU.”

Property Council of Australia, Chief Executive, Mike Zorbas:
“This is a moment of hope and optimism for all Australians and our valued European partners.

The agreement sets the stage for us to welcome a new wave of European capital and expertise into the work of homegrown companies to help us build the best new parts of our growing Australian cities.”

Screen Producers Australia, CEO, Matthew Deaner:
“Screen Producers Australia warmly welcomes this agreement on behalf of Australia’s hundreds of screen businesses.

Our hope is that this agreement will lead to increased co-production and partnership opportunities with European nations with which we have so much shared experience to reflect in our screen stories.

Australian screen businesses already work closely with many EU nations and have a strong foundation to build on.”

Super Members Council, CEO, Misha Schubert:
“For millions of everyday Australians with super, a comprehensive free trade agreement with the EU can help open the door to further investment opportunities that will be hugely important to their retirement incomes.”

The EU already attracts billions of dollars of super investment, and that’s set to continue as Australians’ super funds continue to scour to the globe for the best places to deploy hundreds of billions of dollars more in coming years, offering further opportunities to deliver good long-term, risk adjusted returns for their members.”

Tourism & Transport Forum (TTF), CEO, Margy Osmond:
“It’s fantastic to see the enduring strength of our ties with the European Union, supported by the Federal Government’s ongoing dedication.

Building and strengthening global connections will be critical to Australia’s future success, and agreements like this are an important step forward.

As the peak national industry body for tourism, transport and aviation, we’re focused on ensuring these agreements deliver real outcomes for businesses, workers and communities.”

Joint Industry Statement: Australia–EU Agreements Deliver Opportunity Across the Economy

For further information:
Caragh Heugh Johnson, Director, Policy & Institutional Affairs, EABC
Mobile: +61 425 814 458
Email: cjohnson@eabc.com.au

Australia-EU agreements to benefit Australian’s health with fast tracking of Horizon Europe

Australia-EU agreements to benefit Australian’s health with fast tracking of Horizon Europe

24 March 2026: The finalisation of the Australia-European Union (EU) Free Trade Agreement (FTA) process will benefit the health of Australians through a decision to fast-track negotiations on Australia’s participation with Horizon Europe (HE) – Europe’s flagship research and innovation programme.

Medicines Australia has previously argued strongly for Australia to become associated with Horizon Europe – linking local industry, researchers and innovators into one of the world’s most significant research and innovation ecosystems. This participation would bring major benefits not only to the innovative medicines sector, but also Australia’s broader health and medical research industry.

Chief Executive Officer, Medicines Australia, Liz de Somer, said that with current uncertainty from the Middle East crisis and the potential for ongoing disruption to the medicine supply chain, it is now more critical than ever to expand relationships with Europe.

“Medicines Australia has previously argued for a stronger association with Horizon Europe to help attract extra research and development funding, strengthen regulatory coordination and help create greater opportunities for Australian companies and researchers,” Ms de Somer said.

“We have a responsibility to ensure all avenues are explored when it comes to building relationships with allies across the globe. We must continue to take decisions that support our sovereign capability for medical research and treatments. All Australians depend on it.”

The Medicines Australia Submission to the Department of Industry, Science and Resources notes the benefits of a closer association with HE would:
– Open substantial new funding opportunities for collaborative research and development, particularly benefiting Australian researchers and small and medium enterprises (SMEs) developing new therapeutics.
– Strengthen Australia’s connections with the EU, both scientifically and regulatorily.
– Closer alignment with Europe on health R&D policies would also strengthen Australia’s innovation environment.

Medicines Australia advocates for alignment on scientific and regulatory standards and on policies that incentivise investment in health R&D investment – particularly intellectual property (IP) and data protection.

“The conclusion of the Australia-EU agreements and FTA will benefit all nations and is a clear demonstration of the importance of bi-lateral agreements,” Ms de Somer said.

“Australia is a great trading nation and the FTA, the Security and Defence Partnership and Horizon Europe agreements build upon already strong relationships and help position all nations to meet serious challenges ahead of us.”


Media enquiries:
Anne-Marie Sparrow, Medicines Australia /Cube – media@medicinesaustralia.com.au  or 0417 421 560.

About Medicines Australia:
Medicines Australia leads the research-based pharmaceutical industry of Australia. Our members discover, develop and manufacture the medicines that are the foundation of a healthy and prosperous society, including prescription pharmaceutical products, biotherapeutic products and vaccines. Our members invest in Australian medical research and take local discoveries and developments to the world.

Excellence Recognised in Medicines Australia’s Continuing Education Program

Excellence Recognised in Medicines Australia’s Continuing Education Program

18 March 2026: Medicines Australia celebrates the winners of last year’s Medicines Australia’s Continuing Education Program (CEP) Awards.

These Awards are granted annually to individuals in the pharmaceutical and health sectors to recognise outstanding results during the 2025 academic year of the Medicines Australia CEP.

The Awards include three categories:
– The UTAS Prize for Excellence Award – presented to one student per semester and only applies to programs that require submission of a written assignment
– The Code of Conduct Award – presented to one student who achieves the highest mark for Program 1: Medicines Australia Code of Conduct
– The CEP Award – presented to 10 students who achieve the 10 highest aggregate marks for five core programs. This year, eleven recipients will be recognised, as two students achieved an equal qualifying score.

CEO of Medicines Australia, Liz de Somer explained that the CEP, delivered online through the University of Tasmania (UTAS), equips students with the confidence, skills and knowledge to ensure medical representatives operate to a recognised industry standard.

“We congratulate every one of our award recipients for this remarkable achievement. Their enthusiasm for learning and continuous improvement is genuinely inspiring,” Ms de Somer said.

“The CEP plays a critical role in supporting a highly skilled and ethical industry workforce. This year’s award winners have demonstrated exceptional capability and professionalism.”

Ruth Power was awarded the UTAS Active Learning Prize for Semester 1, while Joshua Hogben from AstraZeneca was awarded the UTAS Prize for Excellence Semester 2.

“While I come from a clinical pharmacy background, the Medicines Australia CEP has given me the confidence to thrive in the pharmaceutical industry as a representative. It has deepened my understanding of how we operate ethically and responsibly, and how we build and maintain trust in our profession and across the industry,” Joshua Hogben said.

On receiving a CEP Achievement Award, Adam Warren explained:

“The Medicines Australia CEP gave me the confidence to have deeper conversations with clinicians. It strengthened my ability to interpret and analyse research, placing me in a much stronger position to contribute meaningfully. It grounds my role and provides me with practical, tangible knowledge – knowledge that enables us to deliver real impact in our work, especially when patient outcomes are paramount

“I also believe it clearly demonstrates our industry’s commitment to training and educating our people so they can have credible, evidence-led conversations with healthcare professionals. Importantly, it reinforces a higher standard of professionalism across the industry.”

The year’s recipient of the Code of Conduct Award was Fiona Gardiner from Eisai Australia.

“This award shines a light on the work our industry does every day – guided by strong principles, committed to doing the right thing, and most importantly, doing the right thing for patients. Ultimately, it strengthens the reputation of our industry,” Fiona Gardiner said.

Ms de Somer said, “I commend Medicines Australia’s member companies for supporting their teams to undertake this critical training, and I congratulate all participants who successfully completed the CEP over the past year.”

Full list of winners re 2025 academic program
Ruth Power – UTAS Prize for Excellence Semester 1
Joshua Hogben (AstraZeneca) – UTAS Prize for Excellence Semester 2
Fiona Gardiner (Eisai Australia) – Code of Conduct Achievement Award
Adam Warren (Chiesi) – CEP Achievement Award
Dileepa Fernando (previously of GSK) – CEP Achievement Award
Kim-Maree Clerke (previously of GSK) – CEP Achievement Award
Leah Jacobsen (previously of AstraZeneca) – CEP Achievement Award
Libby Driffill (BMS) – CEP Achievement Award
Matthew Elias (Vertex) – CEP Achievement Award
Melissa Lim (Arrotex) – CEP Achievement Award
Nick Brown (Arrotex) – CEP Achievement Award
Shae Disney – CEP Achievement Award
Shree Rao (previously of BeOne Medicines) – CEP Achievement Award
Shehan Fernando (previously of Boehringer Ingelheim) – CEP Achievement Award

About the Continuing Education Program (CEP)

Medicines Australia’s Continuing Education Program (CEP) was launched in 1996 and is designed to educate medical representatives working within the prescription medicines industry, to a recognised industry standard.

The program is delivered by our education partner, University of Tasmania. Completion of the CEP is mandatory all medical representatives entering the Australian prescription pharmaceutical industry for the first time.

These courses are also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative.

Courses available include the Medicines Australia Code of Conduct, The Pharmaceutical and Healthcare Industry, Human Anatomy and Physiology, an Introduction to Pharmacology, Product Information, Understanding Product Information, and Understanding Clinical Evidence.

More information is available on Medicines Australia’s website here.


Media enquiries:
Anne-Marie Sparrow, Medicines Australia /Cube – media@medicinesaustralia.com.au  or 0417 421 560.

About Medicines Australia:
Medicines Australia leads the research-based pharmaceutical industry of Australia. Our members discover, develop and manufacture the medicines that are the foundation of a healthy and prosperous society, including prescription pharmaceutical products, biotherapeutic products and vaccines. Our members invest in Australian medical research and take local discoveries and developments to the world.

An ambitious Australia will invest in health and medical life sciences

An ambitious Australia will invest in health and medical life sciences

17 March 2026: Medicines Australia and AusBiotech today welcome the release of Ambitious Australia: Strategic Examination of R&D Final Report and its plan for action to drive Australia’s future innovation investment through greater focus and a healthy appetite for risk and tough decisions.

For too long Australia has traded on being ‘the lucky country’ and Ambitious Australia acknowledges that long term systemic reforms are needed to support Research, Development and Innovation (RD&I) and create sustainable economic growth for future generations.

As the report acknowledges, effective governance structures are required to oversee and drive reform.

“Medicines Australia and AusBiotech support the Report’s first recommendation — to establish a National Innovation Council reporting directly to the Prime Minister, and the Minister for Industry and Innovation and Minister for Science. Buy-in from the top is critical to drive national RD&I effort and achieve investment that improves the productive capacity of Australia’s economy,” said Liz de Somer, CEO Medicines Australia.

“Placing the health and medical sector as central to an Ambitious Australia through its designation as a key national innovation pillar, is central to cementing the whole-of-government focus and partnership with industry that we have been advocating for. It is a critical precursor to driving the scale-up growth, productivity and health security outcomes we know are possible across our thriving health and medical life sciences ecosystem,” said Rebekah Cassidy, CEO, AusBiotech.

Greater coordination and strategic focus have been central to AusBiotech and Medicines Australia’s joint advocacy to the Australian Government, and it is encouraging to see these priorities reflected in the report’s recommendations. Both organisations support the establishment of a National Strategy Advisory Council or Life Sciences Council (Recommendation 1c) that will oversee and drive reforms under the health and medical pillar.

Liz de Somer said: “The rationale for establishing a Life Sciences Council is clear — it will help create the conditions to realise the full potential of Australia’s life sciences industry for Australian patients, harness the productive capacity of Australia’s economy, ensure we can commercialise Australian innovation, and capitalise on the productivity benefits of healthier Australians and health security. Together we must focus RD&I activities on high-risk, high-impact challenges.”

Rebekah Cassidy said: “Without coordinated, whole-of-government action, Australia has risked losing to its global peers, many of which have long identified life sciences as a critical driver of economic growth, global competitiveness and health security. With a rapidly growing pipeline of home-grown start-ups, SMEs and larger companies across biotech, pharma, medtech, and digital health seeking to scale onshore, a whole-of-government strategic focus, with deliberate coordination is needed. The Council must be an enduring forum to foster partnerships across our value chain.”

“The Council has potential to engage all tiers of government, startups, small to medium enterprises, large businesses, investors, and researchers, and will facilitate public-private partnerships to catalyse investments. Now is the time for action,” said Rebekah Cassidy.

We acknowledge Medicines Australia and AusBiotech members, particularly UCB and Bristol Myers Squibb, for their work and advocacy supporting the Life Sciences Council.

Australia needs a new RD&I system, new attitudes to RD&I, new businesses, new opportunities, and new jobs — leading to a better country. AusBiotech and Medicines Australia thank the review chair, Robyn Denholm, and the Expert Panel for this comprehensive review.

Now we must all work together to make lasting change for future generations.


Media inquiries:
AusBiotech Communications Director, Emma Boscheinen / +61 437 075 209 / eboscheinen@ausbiotech.org
Medicines Australia/Cube, Anne-Marie Sparrow / +61 417 421 560 / media@medicinesaustralia.com.au

About AusBiotech
AusBiotech is Australia’s leading national and global advocate for life sciences, working to help its more than 3000 members thrive by shaping policy, creating connections, and fostering knowledge sharing. With an unrivalled national convening power, AusBiotech supports its members’ growth by building an Australian life sciences ecosystem that leads in development and commercialisation, creating high-quality, innovative life sciences companies.

About Medicines Australia:
Medicines Australia leads the research-based pharmaceutical industry of Australia. Our members discover, develop and manufacture the medicines that are the foundation of a healthy and prosperous society, including prescription pharmaceutical products, biotherapeutic products and vaccines. Our members invest in Australian medical research and take local discoveries and developments to the world.

More than 650 gather for AusBiotech and Medicines Australia Women in Life Sciences Luncheon & Leadership Summit

More than 650 gather for AusBiotech and Medicines Australia Women in Life Sciences Luncheon & Leadership Summit

6 March 2026: More than 650 people, from across Australia’s life sciences ecosystem, will gather in Sydney today for the Women in Life Sciences Leadership Summit and Luncheon, hosted by AusBiotech and Medicines Australia.

Held in Doltone House, Sydney to mark International Women’s Day, the events bring together leaders from across biotechnology, pharmaceuticals, medical technologies, digital health, research, and government in a powerful demonstration of sector-wide commitment to advancing women in life sciences.

Today, the Women in Life Sciences Luncheon will welcome 650 attendees, making it one of the largest gatherings of its kind in Australia. The Leadership Summit will bring together 80 participants, reflecting strong demand for practical leadership development and peer connection across the ecosystem.

Aligned with this year’s global theme #GivetoGain, the events champion generosity, collaboration, and shared responsibility as drivers of meaningful progress. The events are also inspired by this year’s call from UN Women to ‘Balance the Scale’, focusing on justice, urging action on the systemic barriers that keep the scales of equality tipped against women and girls.

Speaking at the Luncheon are:

  • Keynote speaker Dr Annalisa Jenkins, OBE, MBBS, FRCP
  • Karyn McIntosh, Director Policy & Government, AusBiotech
  • Dr Ana Svensson, Vice President – Clinical, Medical and Regulatory, Novo Nordisk Pharmaceuticals

Speaking at the Summit are:

  • Keynote speaker Nirelle Tolstoshev, General Manager, Astellas Pharma
  • Lis Boyce, Partner, Piper Alderman; AusBiotech NSW Committee Chair
  • Heidi Bergman, Life Sciences Executive
  • Meredith Crowe, Senior Vice President, Global People & Culture, Telix Pharmaceuticals Limited
  • Louise Hogan, Managing Director, ZRG Partners Australia
  • Erica Bremner Kneipp, Research Director for the Human Health program, CSIRO; Deputy Chair, AusBiotech
  • Professor Robyn Langham AM, Chief Medical Officer, Therapeutic Goods Administration
  • Sue MacLeman, Chair, Medicines Australia
  • Geraldine Murphy, Site General Manager, AstraZeneca
  • Helen Mutimer, Head of IP Advisory, FB Rice

Comments from AusBiotech CEO, Rebekah Cassidy:

“Bringing more than 650 leaders, allies, and changemakers together on International Women’s Day isn’t just an event milestone, it’s a reflection of the wide-ranging commitment our sector holds to advancing the progress of women at all levels.

“I’m grateful to our partners at Medicines Australia, sponsors, and speakers for giving so much to make both the Women in Life Sciences Leadership Summit and the Luncheon, an enormous success again this year.

“And thank you to each of our attendees, for helping create space for connection, honest conversation, and shared learning as we continue accelerate progress, together.”

Comments from Liz de Somer, Chief Executive Officer, Medicines Australia:

“Medicines Australia is delighted to partner with AusBiotech to present the Women in Life Sciences Leadership Summit and Luncheon on International Women’s Day, celebrating the women who continue to shape a more innovative, inclusive and impactful life sciences sector.

“The #GiveToGain theme reminds us that progress comes from mentoring, sharing opportunities and supporting one another. When women advance, we all benefit, so we must continue removing barriers and keeping pathways open for the next generation.

“With 650 guests in attendance and strong engagement from our outstanding speakers, moderators and sponsors at the Luncheon, the event highlights the sector-wide commitment to advancing women in life sciences.”


Media inquiries:
AusBiotech Communications Advisor, Rose Mary Petrass / +61 457 867 78 / rpetrass@ausbiotech.org
Medicines Australia/Cube, Anne-Marie Sparrow / +61 417 421 560 / media@medicinesaustralia.com.au

About AusBiotech
AusBiotech is Australia’s leading national and global advocate for life sciences, working to help its more than 3000 members thrive by shaping policy, creating connections, and fostering knowledge sharing. With an unrivalled national convening power, AusBiotech supports its members’ growth by building an Australian life sciences ecosystem that leads in development and commercialisation, creating high-quality, innovative life sciences companies.

About Medicines Australia:
Medicines Australia leads the research-based pharmaceutical industry of Australia. Our members discover, develop and manufacture the medicines that are the foundation of a healthy and prosperous society, including prescription pharmaceutical products, biotherapeutic products and vaccines. Our members invest in Australian medical research and take local discoveries and developments to the world.

AusBiotech and Medicines Australia expand Women in Life Sciences partnership

AusBiotech and Medicines Australia expand Women in Life Sciences partnership

17 February 2026: AusBiotech and Medicines Australia will again partner to host the Women in Life Sciences Luncheon in 2026 and, for the first time, have expanded their partnership to deliver the Leadership Summit.

Held in New South Wales on 6 March, the two events bring together leaders from across biotechnology, pharmaceuticals, medical technologies, digital health, research, and government to mark International Women’s Day 2026.

Aligned with this year’s global theme #GivetoGain, the program reflects the principle that generosity — through mentorship, advocacy, and the sharing of knowledge and opportunity — is essential to helping women advance. And when women progress, we all gain a stronger, more connected and more equitable sector for everyone.

The events are also informed by UN Women’s call to ‘Balance the Scale’ campaign, highlighting the need to dismantle systemic barriers and discriminatory practices that continue to limit progress for women and girls.

Women in Life Sciences Luncheon

The Women in Life Sciences Luncheon is set to bring together more than 600 leaders, changemakers, and allies to acknowledge the lived experiences of women across the sector.

The Luncheon provides a forum for open discussion, connection and shared learning, recognising that challenges often experienced individually are, in fact, widely shared — and best addressed collectively.

Luncheon keynote speaker announced: Dr Annalisa Jenkins OBE, MBBS, FRCP will deliver the keynote address as this year’s. Dr Jenkins is an internationally recognised life sciences thought leader who operates at the intersection of technology, innovation, and healthcare delivery. She is a board member and investor for multiple companies and funds, Honorary Professor at St. Mary’s University in London and has cultivated roles across Genomics England, The King’s Fund, the British Heart Foundation, Tessa Jowell Foundation and YouBelong. As a Non-Executive Director for Proto Axiom, a Sydney-based biotech investment incubator, Dr Jenkins is also shaping the Australian biotech landscape.

Women in Life Sciences Leadership Summit

For the first time, AusBiotech and Medicines Australia are partnering to deliver the Women in Life Sciences Leadership Summit, focused on equipping mid-level and emerging leaders with the skills, confidence, and connections needed to progress into senior leadership.

The 2026 Summit will explore a number of contemporary themes including:

  • Leading with calm and resilience through uncertainty
  • Making clear decisions when information is incomplete
  • Balancing agility with authenticity in modern leadership
  • Building trust, ethics and human-centred leadership in an AI-enabled world
  • The leadership skills that endure, even as everything else changes

Aligned with #GivetoGain, the Summit emphasises peer learning, shared insight, and the power of connection in accelerating leadership growth across the life sciences ecosystem.

Speakers include:

  • Nirelle Tolstoshev, General Manager, Astellas Pharma Australia
  • Meredith Crowe, Senior Vice President, Global People & Culture, Telix Pharmaceuticals Limited
  • Robyn Langham AM, Chief Medical Officer, Therapeutic Goods Administration
  • Sue MacLeman, Chair, Medicines Australia
  • Geraldine Murphy, Site General Manager, AstraZeneca

Comments from AusBiotech CEO, Rebekah Cassidy:

“The Women in Life Sciences Luncheon and Leadership Summit are part of AusBiotech’s ongoing commitment to actively shaping the future of leadership in our sector.”

“The life sciences sector is built on collaboration, and the #GivetoGain theme reflects a simple but powerful truth: when we give time, visibility, mentorship, and opportunity to women, we strengthen our organisations and our entire ecosystem.

“There is enormous shared opportunity in women, from all parts of our sector, working together to advance health innovation. I’m delighted that AusBiotech is again partnering with Medicines Australia to deliver this year’s luncheon and now partnering on the Leadership Summit. These events create space for honest conversation, collective learning, and connection across our sector.

“By bringing leaders together at different stages of their careers and from different parts of our sector, we can turn individual experience into collective momentum and help build a more inclusive, future-ready life sciences sector.”

Comments from Liz de Somer, Chief Executive Officer, Medicines Australia:

“Our continued collaboration with AusBiotech — including our longstanding support of the Women in Life Sciences Luncheon — reflects a shared commitment to strengthening leadership pathways for women across the life sciences sector. This year, we are particularly proud to expand our partnership to include the Leadership Summit — an important step in reinforcing our shared commitment to practical leadership development and tangible progress for women across the sector.

“Australia’s life sciences community benefits enormously from the expertise, innovation and leadership women bring to research, industry and healthcare. However, meaningful progress requires sustained effort — through sponsorship, advocacy and collective accountability — to remove structural barriers that persist.

“By investing in women’s advancement, and by continuing to show up through initiatives such as the Luncheon and Leadership Summit, we strengthen our sector and deliver better outcomes for patients and the broader community.”

For more information, and to register, click here: https://www.ausbiotech.org/events/event/women-inlife-sciences-2026


Media inquiries:
AusBiotech Communications Advisor, Rose Mary Petrass / +61 457 867 78 / rpetrass@ausbiotech.org
Medicines Australia/Cube, Anne-Marie Sparrow / +61 417 421 560 / media@medicinesaustralia.com.au

About AusBiotech
AusBiotech is Australia’s leading national and global advocate for life sciences, working to help its more than 3000 members thrive by shaping policy, creating connections, and fostering knowledge sharing. With an unrivalled national convening power, AusBiotech supports its members’ growth by building an Australian life sciences ecosystem that leads in development and commercialisation, creating high-quality, innovative life sciences companies.

About Medicines Australia:
Medicines Australia leads the research-based pharmaceutical industry of Australia. Our members discover, develop and manufacture the medicines that are the foundation of a healthy and prosperous society, including prescription pharmaceutical products, biotherapeutic products and vaccines. Our members invest in Australian medical research and take local discoveries and developments to the world.

AusBiotech and Medicines Australia announce members of new joint advisory group to accelerate advanced therapies sector

AusBiotech and Medicines Australia announce members of new joint advisory group to accelerate advanced therapies sector

03 February 2026: AusBiotech and Medicines Australia have today announced the members of their newly established Advanced Therapies Advisory Group.

The Advisory Group will provide input into strategic initiatives that will support Australia’s growing advanced therapies industry, focusing on the findings of the 2025 Australian Cell and Gene Therapies Innovation Investment Report – produced in partnership between AusBiotech, Medicines Australia and Deloitte. The Group will focus on topics related to policy development, advocacy and industry enablement specific to the cell and gene sector in Australia.

In forming the Advisory Group, AusBiotech and Medicines Australia are collaborating to elevate and unify the voice of Australia’s advanced therapies sector.

We recognise the important role of the newly created Solutions for Manufacturing Advanced Regenerative Therapies Cooperative Research Centre (SMART CRC). For this reason, SMART CRC CEO Simon Cool has been invited to join the Group as its inaugural Chair.

Membership comprises senior representatives drawn from across the AusBiotech and Medicines Australia membership bases. They are:

Simon Cool, CEO, SMART CRC (Chair)
Brendon Boot, CEO, Skin2Neuron
Helen Dodds, Clinical Trials Startup Lead, Sanofi
Shanny Dyer, Director, Rheumagen Australia
Dominic Fernandez, Scientific Lead Cell Therapy and Immunotherapy, Epworth Healthcare
Cecile Francis, Director of Partnerships, UniQuest
Kathy Gibson, Executive Director Strategic Medical Engagement, Eli Lilly
Dylan Jones, Country Head of Value and Access, Novartis
Umesh Nair, Major Account Manager, Merck Life Science
Jasmine Oberwalleney, APAC CAR-T Launch Director, Miltenyi Biotec Australia
Gretchen Poortinga, Program Operations Director, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre
Oona Reardon, Director, Pulse Economics Consulting
Warwick Shaw, Market Access Cell and Gene Therapies, Johnson & Johnson
Rebecca Stratford, Head of Market Access, Oncology, AstraZeneca
Stephen Thompson, Chief Executive Director, Viral Vector Manufacturing Facility

AusBiotech CEO, Rebekah Cassidy:
“The new Advanced Therapies Advisory Group will play a key role in developing and advocating for policy outcomes that help to grow Australia’s position as a leader in advanced therapies. AusBiotech is delighted to be collaborating with Medicines Australia to bring the collective expertise of our members together with the SMART CRC. Together we can strengthen opportunities for unified national discussion regarding the development of this sector and, importantly, enable improved Australian patient access to cell and gene technologies.”

Medicines Australia CEO, Elizabeth de Somer:
“Collaboration is essential to maintain momentum in the delivery of advanced therapies – cell and gene technologies – to the community. This Advisory Group represents a very important step forward in unifying industry and other stakeholders to consider and address critical policies and delivery mechanisms to ensure we fully harness and maximise these important therapeutics now and into the future.”

SMART CRC CEO, Professor Simon Cool:
“The SMART CRC is delighted to join AusBiotech as the voice of 63 partners advancing Australia’s regenerative therapy manufacturing capability. With a decade-long pipeline of collaborative projects, we are committed to translating therapies to patients. Partnering with AusBiotech and Medicines Australia is a critical step towards accelerating medical innovation, creating jobs, and building a highly skilled workforce. We look forward to working together to deliver a lasting national impact.”

The Advisory Group will provide a unified voice to government, industry, and the community, ensuring Australia seizes the opportunity to become a leading hub for advanced therapies and delivers better health outcomes for patients.

This announcement follows an expression of interest process open to AusBiotech and Medicines Australia members in late 2025.


Media inquiries:
AusBiotech Communications Advisor, Rose Mary Petrass / +61 457 867 78 / rpetrass@ausbiotech.org
Medicines Australia, Anne-Marie Sparrow / +61 417 421 560 / media@medicinesaustralia.com.au

About Medicines Australia:
Medicines Australia leads the research-based pharmaceutical industry of Australia. Our members discover, develop and manufacture the medicines that are the foundation of a healthy and prosperous society, including prescription pharmaceutical products, biotherapeutic products and vaccines. Our members invest in Australian medical research and take local discoveries and developments to the world.

About AusBiotech
AusBiotech is Australia’s leading national and global advocate for life sciences, working to help its more than 3000 members thrive by shaping policy, creating connections, and fostering knowledge sharing. With an unrivalled national convening power, AusBiotech supports its members’ growth by
building an Australian life sciences ecosystem that leads in development and commercialisation, creating high-quality, innovative life sciences companies.

About SMART CRC:
The Solutions for Manufacturing Advanced Regenerative Therapies (SMART) Cooperative Research Centre (CRC) is a nationally coordinated initiative that brings together expertise from across the regenerative therapy value chain. With 63 foundation partners spanning industry, government and research, the SMART CRC fosters collaboration to grow Australia’s regenerative therapy ecosystem, accelerate breakthrough technologies and deliver life-changing treatments. Together, we will mature a self-sufficient, sustainable pipeline of technologies and talent, unlocking its full potential to benefit Australia’s economy, healthcare, and patients.

Medicines Australia publishes Annual Report and announces new Board Directors

Medicines Australia publishes Annual Report and announces new Board Directors

29 October 2025: Medicines Australia has published their Annual Report for the year ended 30 June 2025 and welcomed two new Directors to its Board, at their Annual General Meeting (AGM) today.

Joana De Castro (Senior Vice President and Managing Director ANZ, Johnson & Johnson Innovative Medicine) and Melissa McGregor (General Manager, ANZ, Chiesi Australia), have been elected to join the Board. They replace Nathalie McNeil (Vice President and General Manager ANZ, AbbVie) and Josie Downey (General Manager and Managing Director, Merck), who both served for a full 3 year term.

Chair and Director of Medicines Australia, Sue MacLeman, welcomed the newly elected Directors at the AGM.

“On behalf of the Board and the Medicines Australia membership, I congratulate and welcome the newly elected Directors” Sue MacLeman said.

“I sincerely thank the outgoing Directors for their leadership and bringing valuable experience and insight to the Board. We are very grateful for their service and contributions.”

At the AGM, Ms MacLeman shared her first report as Chair for Medicines Australia, articulated the organisation’s progress over the past financial year and thanked members for their welcome and ongoing contributions to Medicines Australia. Ms MacLeman said “Thankyou for your ongoing commitment and contribution to Medicines Australia. I am confident in the strength and unity of our Board, members, and leadership team. Together, we will continue to champion policies that support innovation, a sustainable and thriving innovative medicines sector in Australia, and better health outcomes for all Australians.”

Medicines Australia Annual Report 2024-2025


Media enquiries to: Anne-Marie Sparrow, Medicines Australia /Cube – media@medicinesaustralia.com.au or 0417 421 560

About Medicines Australia

Medicines Australia leads the research-based pharmaceutical industry of Australia. Our members discover, develop and manufacture the medicines that are the foundation of a healthy and prosperous society, including prescription pharmaceutical products, biotherapeutic products and vaccines. Our members invest in Australian medical research and take local discoveries and developments to the world.